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In recent years, several lines of evidence have established the rela-
tionship of neurotrophins with both anxiety and drug abuse disor-
ders (Chao, 2003; Chao et al., 2006). This peptide family includes 
nerve growth factor, brain-derived neurotrophic factor (BDNF), 
neurotrophin-3 (NT-3), neurotrophin-4/5 (Binder and Scharfman, 
2004). Neurotrophins selectively interact with their individual high-
afﬁ  nity protein kinase receptors of the Trk family (Kaplan and 
Miller, 2000; Chao, 2003; Teng and Hempstead, 2004), so that BDNF 
and NT-3 mediate their biological effects via TrkB and TrkC high-
afﬁ  nity receptors respectively (Dechant and Barde, 2002). Human 
genetic studies have recently conﬁ  rmed the association of BDNF 
gene variants and the NTRK2 gene to substance-related and other 
neuropsychiatric disorders (Zhang et  al., 2006; Gratacos et  al., 
2007). Moreover, BDNF and NT-3-signaling pathways participate 
in opiate-induced adaptations of the catecholaminergic system in 
vitro (Sklair-Tavron and Nestler, 1995) and in vivo (Berhow et al., 
1995; Sklair-Tavron et al., 1996). In mice with conditional ablation 
of NT-3 in brain, the somatic symptoms of opiate withdrawal are 
attenuated, in conjunction with reduced upregulation of tyrosine 
hydroxylase (TH) expression in LC (Akbarian et al., 2001). This 
phenotype is restored by transgene-derived NT-3 expression. On 
the other hand, the LC expresses high levels of the mRNAs of BDNF 
and NT-3 and their high-  afﬁ  nity receptors (Seroogy et al., 1994; 
Smith et al., 1995; Zhang et al., 1998) and both neurotrophins 
increase survival of LC neurons in vitro (Friedman et al., 1993; 
INTRODUCTION
There is a high rate of co-occurrence between substance abuse and 
other psychiatric disorders (Regier et al., 1990; Kessler et al., 1994; 
Kandel et al., 2001) such as anxiety and panic disorder (Cottler et al., 
1992; Kushner et al., 2000; Breslau et al., 2003; Zvolensky et al., 2005, 
2006). Based on clinical data, it has been proposed that deregula-
tion of the opioid system at the brainstem level may potentially 
underlie critical aspects of panic disorder’s neurobiology includ-
ing respiratory abnormalities and sensitivity to suffocation. The 
locus coeruleus (LC) underlies the physiologic and affective changes 
seen in opiate withdrawal and in panic attacks (Aghajanian, 1978; 
Aghajanian and Wang, 1986; Gear et al., 1995; El-Kadi and Sharif, 
1997; Nakai et al., 2002) and could be a common structure for both 
processes so that withdrawal syndrome and panic attacks may be dif-
ferent symptomatic expressions of similar neurobiological mecha-
nisms. So, in subjects with overactivity of endogenous opioid system, 
naltrexone might induce panic attacks by removing this inhibitory 
effect (Aghajanian, 1978; Arntz et al., 1993; Maremmani et al., 1998; 
Sinha et al., 2007) on noradrenergic neurons in the LC. Moreover, 
studies focused on the treatment of pain, the most frequent fear of 
dying patients have used morphine to reduce states of panic (Roller, 
2000), as well in studies with rats in which morphine administration 
inhibited the dorsal periaqueductal grey (dPAG), a brain region 
responsible for the escape behavior that is thought to be related to 
fear and panic (Nicolas et al., 2007).
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Sklair-Tavron and Nestler, 1995). Noradrenergic LC neurons of 
BDNF-deﬁ  cient mice respond to chronic morphine treatment with 
a paradoxical down regulation of cAMP-mediated excitation and 
lack of dynamic regulation of TH, and these mice also have reduced 
opiate withdrawal symptoms despite normal antinociceptive toler-
ance (Akbarian et al., 2002).
In the present study, we have used transgenic mice overexpress-
ing TrkC (TgNTRK3), a model of panic disorder (Dierssen et al., 
2006; Sahún et al., 2007b), to test the hypothesis that the LC opioid 
system might be altered with an impact on opiate dependence as 
previously suggested in human patients.. We have characterized the 
behavioral and electrophysiological responses to acute and chronic 
morphine treatment and during opiate withdrawal along with the 
changes in expression of BDNF, NT-3 TrkB and TrkC mRNAs. 
Our work highlights the implication of TrkC in panic disorder 
and substance abuse.
MATERIALS AND METHODS
ANIMALS
Same sex hybrid B6/SJL-F1J mice were housed in groups of 3–5 
animals per cage in standard Macrolon® cages (40 cm long × 25 cm 
wide × 20 cm high) under a 12 h light/dark schedule (lights on 
08:00 to 20:00) in controlled environmental conditions of humid-
ity (50%–70%) and temperature (22 ± 2ºC) with food and water 
supplied ad libitum. The production TgNTRK3 mice has previ-
ously been described (Dierssen et al., 2006). Brieﬂ  y, TgNTRK3 mice 
were obtained as heterozygotes on a B6/SJL-F1J genetic background 
(Charles River, Barcelona, Spain). Hybrid founders were crossed 
using B6/SJL-F1J females and all experiments were performed using 
male mice from the F16–F20 generation to attenuate littermate’s 
genetic differences. The non-transgenic (WT) littermates obtained 
from crosses of males TgNTRK3 mice and B6/SJL-F1J females 
served as controls. All experimental procedures were approved by 
the local ethics committee (CEEA-IMIM and CEEA-PRBB), and 
met the guidelines of the local (Catalan law 5/1995 and Decrees 
214/97, 32/2007) and European regulations (EU directives 86/609 
and 2001–486) and the Standards for Use of Laboratory Animals nº 
A5388-01 (NIH). The CRG is authorized to work with genetically 
modiﬁ  ed organisms (A/ES/05/I-13 and A/ES/05/14).
DRUGS
Morphine was provided by the Ministerio de Sanidad y Consumo 
(Spain). Naloxone and Met5-enkephalin (ME) was purchased from 
Sigma Chemical Co. (Madrid, Spain). Both compounds were dis-
solved in physiological saline (0.9% NaCl).
CHARACTERIZATION OF THE TgNTRK3 BEHAVIORAL RESPONSE TO 
OPIATES
For the pharmacological in vivo study of opiate effects in TgNTRK3 
mice we used 15–20 male mice of 2–4 months of age per group of 
treatment and genotype.
Acute effects of morphine
We evaluated the acute effects of morphine (10 mg/kg, s.c.) on 
nociception using the tail immersion and hot plate tests and on 
locomotion in WT and TgNTRK3 mice. For the hot plate test we 
used different doses of morphine in order to avoid a ceiling effect 
(2.5, 5, and 10 mg/kg, s.c.). For the tail immersion test, mice were 
gently placed in a restrainer cylinder and the nociceptive thresh-
old was assessed as described previously (Florez et al., 1990; Ruiz 
et al., 1993; Simonin et al., 1998) by measuring the time to with-
draw the tail immersed in a thermostatically controlled water bath 
(50 ± 0.1ºC; Clifton, Scientiﬁ  c Instruments, England), with a cutoff 
latency of 15 s to prevent tissue damage. We also used a hot plate 
analgesic meter (Columbus, OH, USA) that consisted of a glass 
cylinder (19-cm high, 19-cm diameter) to keep the mice on the 
heated surface of the plate (52 ± 0.1ºC). Two nociceptive indexes, 
licking of the paws and jumping, were registered. The cutoff latency 
was of 30 s for the licking response and of 240 s for the jumping 
response, respectively. Locomotor responses were evaluated using 
activity boxes (9 cm long × 20 cm wide × 11 cm high; Imetronic, 
Lyon, France); with a line of photocells 2 cm above the ﬂ  oor to 
measure horizontal movements and another line located 6 cm 
above the ﬂ  oor to measure vertical activity (rearing). On the test-
ing day, the mice were individually placed in the boxes and the 
total locomotor activity (ambulatory movements plus horizontal 
movements) was recorded for 30 min in a low luminosity environ-
ment (5–15 Lux).
In order to habituate the animals to the test environment and 
to obtain a stable baseline, tail immersion response and locomotor 
activity were measured for 2 days before the experiment. Saline 
injections were given on these days. On the experimental day, loco-
motor activity was evaluated immediately after morphine injec-
tion (10 mg/kg, s.c.) during 30 min. Then, tail immersion test was 
performed, followed by the hot plate test.
Tolerance and sensitization to morphine effects
Tolerance refers to drug-induced adaptations that lead to dimin-
ishing effects of a constant, repeated drug dose. Sensitization, or 
reverse tolerance, refers to drug-induced adaptations that enhance 
drug responsiveness with repeated drug exposure (Dierssen et al., 
1990). Morphine causes both tolerance and sensitization, with 
antinociceptive effects decreasing over time while locomotor 
activity increases. As for the previous experiment, basal tail immer-
sion response and locomotor activity were evaluated for 2 days 
before the initiation of the chronic morphine treatment on day 1. 
Morphine (10 mg/kg, s.c.) was administered chronically twice a day 
(12 h inter-injection interval) for 7 days. Locomotor activity was 
recorded immediately after the morning injection of morphine, as 
described above. Changes in nociceptive threshold were assessed 
30 min later using the tail immersion test (days 1–7).
Naloxone-precipitated morphine withdrawal
The naloxone-precipitated withdrawal syndrome in morphine-
dependent mice was evaluated as previously described (Maldonado, 
1997). Brieﬂ  y, behavioral ratings were calculated over a 15 min 
period by a trained observer blind to the genotype. The animals 
were placed individually into test chambers consisting of transpar-
ent plastic cylinders (50 cm high, 30 cm diameter) with a white 
ﬂ  oor, to evaluate the behavioral signs of withdrawal. Behavioral 
responses were recorded in two sessions: 15 min before naloxone 
injection and the 30 min after injection. Wet dog shakes, jumping, 
paw tremor and snifﬁ  ng were quantiﬁ  ed. Ptosis, diarrhea, teeth 
chattering, body tremor and piloerection were evaluated over Frontiers in Behavioral Neuroscience  www.frontiersin.org  February 2010  | Volume 3  |  Article 60  |  3
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5 min periods with the presence of each sign during each period 
being scored as 1. The numbers of periods showing each sign were 
then counted (maximum score = 6). A global withdrawal score, 
determined by all the checked signs was calculated individually 
for each mouse. To obtain this global value and to assign a pro-
portional weight to all the signs, the score obtained from each sign 
was multiplied by a constant as previously reported (Maldonado 
et al., 1996). Naloxone-precipitated withdrawal was evaluated after 
two different treatment regimes of morphine as follows in order 
to avoid ceiling effects on withdrawal symptoms that would blind 
possible differences between genotypes.
Naloxone-precipitated morphine withdrawal after increas-
ing doses of morphine. Morphine was injected i.p. twice a day 
(12-h inter-injection interval) for 6 days. The morphine dose 
was progressively increased as follows: 1st day, 20 mg/kg/injec-
tion??; 2nd day, 40 mg/kg; 3rd day, 60 mg/kg; 4th day, 80 mg/kg; 
5th day, 100 mg/kg; 6th day (only morning injection), 100 mg/kg. 
Control mice of both genotypes were treated with saline using 
the same injection schedule. Withdrawal was precipitated in each 
animal by injecting naloxone (1 mg/kg, s.c.) 2 h after the last 
morphine administration.
Naloxone-precipitated morphine withdrawal after constant dose 
of morphine. Morphine was injected i.p. twice a day (12-h inter-
injection interval) for 6 days. In this experimental group, the dose 
of morphine was constant (20 mg/kg/injection?) during the 6 days. 
Control mice of both genotypes were treated with saline using 
the same injection schedule. Withdrawal was precipitated in each 
animal by injecting naloxone (1 mg/kg, s.c.), 2 h after the last mor-
phine administration.
Anxiety-like behavior during morphine withdrawal. The anxio-
genic effects of morphine withdrawal were studied using the zero-
maze test immediately after evaluation of withdrawal symptoms, 
in animals receiving constant doses of morphine (20 mg/kg; see 
Naloxone-precipitated morphine withdrawal after constant dose 
of morphine). The zero-maze consisted of a circular path (runway 
width 5.5 cm, 46 cm diameter) with two open and two closed seg-
ments (walls 8 cm high) and was elevated 50 cm. Animals were 
placed into the closed segments and their movements analyzed 
for 5 min. The experiment was carried out in a dimly lit room to 
minimize any effects of stress/anxiety and data were scored with 
the aid of a video camera. The latency to enter the open segment, 
the number of crossings and the time spent in the open segments 
were recorded. An open segment visit was scored when the mouse 
moved all four paws into the segment.
IN SITU HYBRIDIZATION
Three TgNTRK3 and 3 WT littermates were used for each treat-
ment condition following the increasing dose morphine injection 
schedule detailed in Section “Naloxone-precipitated morphine 
withdrawal after increasing doses of morphine”. Animals were 
killed 2 h after naloxone injection to study morphine withdrawal 
or 4 h after the last morphine injection to study chronic morphine 
effects. The same schedule was used in the saline-treated group. 
Then, brains were dissected out and frozen in dry ice and serial 
coronal cryostat sections (14 µm) were processed for TrkB, TrkC, 
NT-3, and BDNF riboprobes as follows. After rinsing in PBS, tissue 
was deproteinated in 0.2 M HCl for 10 min, acetylated with 0.25% 
acetic anhydride in 0.1 M ethanolamine for 10 min, post-ﬁ  xed in 
4% paraformaldehyde, and dehydrated with increasing concentra-
tions of ethanol. Slices were incubated for 16 h in a humidiﬁ  ed 
chamber at 53°C with 3 × 105 c.p.m. of antisense probes in 150 µL 
of hybridization cocktail (50% formamide, 20 mM Tris-HCl, pH 
7.6, 1 mM EDTA, pH 8.0, 0.3 M NaCl, 0.1 M dithiothreitol, 0.5 mg/
mL yeast tRNA, 0.1 mg/mL poly (A+) RNA, 1 × Denhardt’s solu-
tion, and 10% dextran sulfate). Antisense cRNA probes to detect 
the transcript were prepared by in vitro transcription using T7 
RNA polymerase (Promega, WI, USA) and [35S] UTP (Amersham 
Pharmacia Biotech, Uppsala, Sweden). The TrkB probe recognized 
both full-length and truncated isoforms (Lindefors et al., 1995) and 
the TrkC probe detected all TrkC receptor forms (Laurenzi et al., 
1994). For control experiments, sense cRNA probe was obtained 
by in vitro transcription using T3 RNA polymerase (Promega, WI, 
USA). After hybridization, slices were ﬁ  rst washed at room tem-
perature in 1 × SSC, followed by two washes in 1 × SSC at 37°C for 
15 min each. Single-stranded RNA was digested by RNase treat-
ment (40 µg/mL) for 30 min at 37°C in 0.5 M NaCl, 20 mM Tris-
HCl, pH 7.6, and 2 mM EDTA. Tissue was washed twice in 1 × SSC 
in 65°C for 10 min, dehydrated in ethanol, and air-dried. Slices 
were exposed to β-max x-ray ﬁ  lm (Amersham Pharmacia Biotech, 
Uppsala, Sweden) for 20 days and dipped in LM-1 photoemulsion 
(Amersham Pharmacia Biotech, Uppsala, Sweden), exposed at 4°C 
for 2 months, developed with D19 (Eastman Kodak), ﬁ  xed, and 
counterstained with cresyl violet staining. Consecutive slices were 
stained against TH in order to delimit the LC and thus allowing 
an accurately quantiﬁ  cation of this region.
QUANTITATIVE-PCR
To determine changes in endogenous TrkC receptors [full length 
(TrkC FL) and truncated (TrkC TF)], quantitative-PCR was car-
ried out in duplicate in brainstem from adult (2–4 month of age) 
TgNTRK3 (n = 4) and WT mice (n = 3) with the cDNA solu-
tion using the LightCycler® 480 SYBR Green I Master kit (Roche 
Diagnostics GmbH, Mannheim, Germany) in a LightCycler® 480 
Real-Time PCR system (Roche Diagnostics GmbH, Mannheim, 
Germany) according to the manufacturer’s recommendations, 
except that the ﬁ  nal volume of the reaction was 20 µL in order to 
avoid errors due to high volumes. The cDNA solution was submitted 
to 45 cycles of PCR ampliﬁ  cation by using speciﬁ  c primers from the 
endogenous TrkC: TrkC FL -F 5′- ACCGGAAGTTCACCACAGAG 
-3′ and TrkC FL -R 5′- GCAGACTCTGGGTCTCTCCA -3′; TrkC 
TF -F 5′- CCAGAGTGGGGATGTGTCTT -3′ and TrkC TF -R 5′- 
CCATGGTTAAGAGGCTTGGA -3′. The Pgk1 gene was used as 
the reference gene. Final volume was 20 µL, with 1 µL of one-tenth 
H2O-diluted cDNA from reverse transcription reaction, 0.3 µmol/L 
of each speciﬁ  c primer, and 10 µL 2 × SYBR Green I Master solu-
tions. Quantitative-PCR cycles were set at 10 min denaturation 
followed by 45 cycles of 95ºC for 10 s, 61ºC for 15 s, and 72ºC for 
10 s and 95ºC. Dissociation curves were inspected for each pair of 
primers, and only dissociation peak must be present for each run 
of reaction before the results were considered to be valid. A 4-fold 
serial dilution of a reference sample was used for construction of Frontiers in Behavioral Neuroscience  www.frontiersin.org  February 2010  | Volume 3  |  Article 60  |  4
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standard curves with respect to each pair of primers. All samples 
were ampliﬁ  ed in duplicate and the CT mean was obtained for 
further calculations. Duplicates with SD ≥ 0.38 were excluded, and 
the corresponding samples were re-ampliﬁ  ed. The ΔΔCt method 
[Relative Expression Software Tool (REST)] was used to quantify 
the relative amount of mRNA in each sample in comparison with 
the control samples. Next, 2−ΔΔCt of each gene was transformed 
into logarithmic scale (log 2 ratio).
ELECTROPHYSIOLOGICAL STUDIES
Single-unit extracellular recordings of LC neurons were per-
formed in slices from saline treated (WT n = 16 and TgNTRK3 
n = 12) and morphine-treated (WT n = 16; TgNTRK3 n = 16) 
mice, as previously described (Pineda et al., 1996) and follow-
ing the increasing dose morphine injection schedule of Section 
“Naloxone-precipitated morphine withdrawal after increasing 
doses of morphine”. Brieﬂ  y, mice were anesthetized with chlo-
ral hydrate (400 mg/kg, i.p.) and decapitated 1–4 h after the last 
injection of morphine. Coronal slices (400 µm) of the brainstem 
including the LC were prepared with a vibratome and incubated 
in a Haas-type gas-liquid interface chamber at 33ºC, which was 
continuously perfused with artiﬁ  cial cerebrospinal ﬂ  uid (aCSF) 
at a ﬂ  ow rate of 1–1.5  mL/min (saturated with 95% O2/5% 
CO2). The aCSF was composed of: 129 mM NaCl, 3 mM KCl, 
1.25 mM NaH2PO4, 2 mM MgSO4, 2 mM CaCl2, 22 mM NaHCO3 
and 10 mM D-glucose. The extracellular signal was recorded by 
blunt-tipped Omegadot glass micropipettes ﬁ  lled with a 50 mM 
NaCl solution (3–5 MΩ), and then monitored through a high-
input impedance ampliﬁ  er on an oscilloscope and also with an 
audio unit. Individual neuronal (single-unit) spikes were isolated 
from the background noise with a window discriminator and the 
ﬁ  ring rate was analyzed by means of a PC-based custom-made 
program, which generated rate bar histograms in consecutive 
10-s bins (HFCP®, Cibertec S.A., Madrid, Spain). The LC was 
identiﬁ  ed visually in the rostral pons as a dark oval area on the 
lateral borders of the central gray and the 4th ventricle, immedi-
ately anterior to the genu of the facial nerve. LC cells displayed 
spontaneous ﬁ  ring activity at regular rhythms and long-lasting 
positive-negative waveforms.
Opioid withdrawal was spontaneously precipitated in vitro on 
the slice preparation in chronic morphine-treated mice of both 
genotypes by allowing morphine to wash out for 90 min before 
recordings (Kogan et al., 1992). Next, consecutive neurons were 
sampled during in vitro opiate withdrawal for about 90 min by mul-
tiple electrode tracks randomly positioned within the LC. Complete 
washout of residual morphine was conﬁ  rmed at the end of each 
experiment by testing the lack of naloxone (1 µM) effect. To evaluate 
opiate tolerance in the LC, concentration-effects curves were con-
structed for the inhibitory effect of the µ-opioid receptor (MOR) 
agonist ME on the LC in saline and chronic morphine-treated mice 
of both genotypes following the increasing dose morphine injection 
schedule of Section “Naloxone-precipitated morphine withdrawal 
after increasing doses of morphine”. Increasing concentrations of 
ME (0.1–100 µM) were added at 5 min intervals until a maximal 
effect was reached. ME was chosen because its washout is very 
rapid even at high concentrations and its action is mediated almost 
exclusively by MOR in the LC (Williams and North, 1984).
DATA ANALYSIS AND STATISTICAL EVALUATION
All values are given as mean ± SEM. For the behavioral studies, 
data obtained from the tail immersion and the hot plate tests were 
expressed as the percentage of maximal possible effect (% MPE). 
The calculation of the % MPE was performed using the following 
formula: [(test latency – control mean latency)/(cutoff – control 
mean latency)] × 100. For data obtained from acute morphine 
administration, a two-way analysis of variance (ANOVA) was 
used to determine the interaction between genotype and treat-
ment. Posterior Student’s t test was used to determine differences 
between TgNTRK3 and WT mice. The development of tolerance to 
morphine antinoception in the tail immersion test and the devel-
opment of locomotor sensitization in activity cages were analyzed 
by using a General Linear Model  – Repeated Measures analysis in 
order to detect differences between curves across days. Two-way 
ANOVA was used to determine the interaction between treatment 
and genotype. Data related to the total score obtained from with-
drawal signs were analyzed by using Student’s t test. Levels of NT-3, 
BDNF and their receptors, TrkC and TrkB mRNAs were analyzed 
by using one-way ANOVA for the treatment and Student’s t test for 
the genotype. Bonferroni post hoc was used when necessary. Results 
from quantitative RT-PCR analysis were obtained in the Relative 
Expression Software Tool – 384 (REST-384© v.2), and analyzed 
using Pair Wise Re-allocation Randomisation Test©.
For the electrophysiological studies, the basal ﬁ  ring rate was 
obtained in each cell by averaging the values from the rate bars 
recorded for at least 60 s in the absence of any drug, so that the 
stability of the discharge was ensured. To evaluate opiate with-
drawal in the LC, the mean ﬁ  ring rate of all cells sampled in each 
slice was considered as an individual data point and used for the 
statistical analysis. The inhibitory effect of each ME concentration 
was calculated as the percentage of the reduction of ﬁ  ring rate 
from the baseline. In these assays, the ﬁ  ring rates after each ME 
application was the average value obtained from the rate bars in 
9 consecutive bins after the onset of the perfusion. Curve ﬁ  tting 
analysis was performed by the computer program GraphPad Prism 
(version 3.0 for Windows, San Diego, USA) to obtain the best simple 
nonlinear ﬁ  t to the following three-parameter logistic equation: 
E = Emax/[1 + (EC50/A)n], where E is the effect induced by each 
concentration of ME (A), Emax is the maximal effect, EC50 is the 
concentration of the agonist needed to elicit a 50% of the maximal 
effect and n is the slope factor of the concentration-effect curve. 
Emax was constrained to be 100% since the maximal inhibition 
was always complete. For statistical analysis, the EC50 values were 
transformed to the corresponding logarithmic data to convert them 
to a Gaussian distribution. Data among groups were compared by 
one-way ANOVA followed, when signiﬁ  cant, by a Student’s t test 
(for concentration-effect curve parameter evaluations) or a Tukey’s 
multiple comparison t test (for ﬁ  ring rate evaluations). Probability 
values lower than 0.05 were accepted as signiﬁ  cantly different.
RESULTS
THE ACUTE ANTINOCICEPTIVE EFFECTS OF MORPHINE WERE SLIGHTLY 
ATTENUATED IN TgNTRK3
The acute effects of morphine were evaluated by the changes induced 
in nociception (Figure 1) and locomotor activity (Figure 2A). In 
the hot plate test, two-way ANOVA revealed no interaction between Frontiers in Behavioral Neuroscience  www.frontiersin.org  February 2010  | Volume 3  |  Article 60  |  5
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FIGURE 2 | Tolerance to morphine-induced antinociception and sensitization 
to locomotor effects. Mice received repeated morphine (10 mg/kg, s.c.) or saline 
injections twice a day for 7 days. (A) Locomotor activity was measured in activity 
cages during 30 min after the morning injection of morphine during 7 days. (B) 
Nociceptive threshold was determined during the 7 days of morphine 
administration after measuring locomotor activity, by means of the tail immersion 
test. Data are expressed as means ± SEM of the maximum possible effect (MPE 
%) for the antinociceptive effect or the distance traveled (cm) for locomotor activity.
FIGURE 1 | Acute antinociceptive effect of morphine (Mf, 10 mg/kg, s.c.). 
Two behavioral tests were used in WT (white bars) and TgNTRK3 (black 
bars): the hot plate test in which (A) the licking and (B) the jumping 
threshold were recorded, and (C) the tail immersion test where the 
tail withdrawal latency is given. Antinociceptive effects were evaluated 
30 min after morphine injection. Data are expressed as means ± SEM of 
the maximum possible effect (MPE %). *p < 0.05 (Student’s t test, WT vs. 
TgNTRK3 mice).
genotype and treatment in any of the responses (F(2,89) = 0.04, n.s., 
jumping, and F(2,89) = 1.27, n.s., licking). However, the licking response 
(Figure 1A), which is highly sensitive to analgesic agents and is con-
sidered an accurate measure of antinociceptive potency in rodents, 
showed a signiﬁ  cantly reduced antinociceptive effect of acute admin-
istration of 10 mg/kg morphine in TgNTRK3 mice (t(1,47) = 2.02, 
p < 0.05, Student’s t test). Besides, no differences between genotypes 
were observed when using neither 2.5 nor 5 mg/kg of morphine Frontiers in Behavioral Neuroscience  www.frontiersin.org  February 2010  | Volume 3  |  Article 60  |  6
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(t(1,20) = 0.04, n.s., and t(1,18) = –0.59, n.s., respectively, Student’s t test) 
in independent groups of mice. Regarding the jumping response, 
the higher doses of morphine (5 and 10 mg/kg) showed a ceiling 
effect (Figure 1B). However, when using a dose of 2.5 mg/kg of 
morphine no signiﬁ  cant differences were observed between geno-
types (t(1,20) = 0.18, n.s., Student’s t test). In the tail immersion test 
(Figure 1C) no signiﬁ  cant differences in the acute antinociceptive 
effects of morphine were observed between genotypes as reﬂ  ected by 
a similar tail withdrawal latency (t(1,48) = 0.66, n.s., Student’s t test).
The analysis of locomotor activity revealed that the acute effect of 
morphine on locomotion was similar between genotypes (F(1,107) = 0.81, 
n.s., two-way ANOVA, Figure 2A). An independent experiment meas-
uring locomotor activity during longer time periods (during 60 min 
after morphine administration) also did not show differences between 
genotypes (Figure S1 in Supplementary Material)
MORPHINE-INDUCED LOCOMOTOR SENSITIZATION AND DEVELOPMENT 
OF TOLERANCE TO MORPHINE ANTINOCICEPTION WERE NOT MODIFIED 
BY THE OVEREXPRESSION OF NTRK3
We monitored the development of tolerance and sensitization 
over the course of 7 days, induced by daily injections of morphine 
(10 mg/kg twice-a-day). Locomotor activity was measured after 
saline or morphine injection during the ﬁ  rst hours of the light phase 
(Figure 2A). Animals of either genotype were habituated to the 
activity cages during 2 days showing a reduction in total locomotor 
activity between the ﬁ  rst and second day (F(1,106) = 76.91, p < 0.001, 
ANOVA repeated measures). The habituation to the apparatus was 
similar in both genotypes (F(1,106) = 0.13, n.s., one-way ANOVA). 
Morphine administration along 7 days after habituation elicited 
sensitization to total locomotor activity in WT and TgNTRK3 
mice when compared to saline groups (F(7,97) = 3.02,  p < 0.01; 
ANOVA repeated measures) with no differences between geno-
types (F(7,97) = 0.04, n.s. two-way ANOVA). Moreover, no differences 
between genotypes were observed along the 7 days of treatment in 
neither morphine groups (F(7,42) = 0.43, n.s., one-way ANOVA) or 
saline groups (F(7,49) = 1.01, n.s., one-way ANOVA). Locomotor sen-
sitization also was studied changing the administration protocol. 
In this experiments, when morphine (10 mg/kg) was administered 
only once every 2 days again no differences were observed between 
genotypes (Figure S1 in Supplementary Material).
Development of tolerance was studied measuring antinociception 
with the tail immersion test (Figure 2B). During the ﬁ  rst 2 days mice 
of either genotype did not show differences in the habituation to the 
apparatus (F(1,120) = 0.23, n.s., one-way ANOVA). Both TgNTRK3 and 
WT mice exhibited a progressive loss of morphine antinociceptive 
effect along sessions in the tail immersion test as reﬂ  ected by no dif-
ferences in the reduction of the %MPE (F(7,41) = 0.31, n.s., ANOVA 
repeated measures). Saline-treated mice also showed no genotype 
differences during the 8 days (F(7,62) = 0.04, n.s., one-way ANOVA). 
Two-way ANOVA repeated measures revealed no interaction between 
treatment and genotype (F(7,109) = 0.42, n.s.) along days.
NALOXONE-PRECIPITATED WITHDRAWAL SYNDROME AFTER INCREASING 
DOSES OF MORPHINE WAS SIMILAR IN TgNTRK3 AND WT MICE
In the ﬁ  rst experiment, withdrawal was induced after 6 days of pro-
gressively increasing doses of morphine with a subcutaneous injec-
tion of naloxone 2 h after the last morphine injection (Figure 3A). 
Both WT and TgNTRK3 mice showed the   characteristic signs of 
opiate withdrawal, including autonomic hyperactivity, wet dog 
shakes, paw tremor, piloerection, jumps, and other withdrawal-
related behaviors. No differences between genotypes were observed 
in the score obtained for each behavioral sign checked. The total 
withdrawal score was similar for the TgNTRK3 and WT mice 
(F(1,79) = 0.82, n.s., two-way ANOVA).
NALOXONE-PRECIPITATED WITHDRAWAL SYNDROME WAS INCREASED 
AFTER BY CONSTANT DOSES OF MORPHINE IN TgNTRK3 MICE
In order to discard a possible ceiling effect on withdrawal symptoms 
after dependence induced by increasing dose of morphine, we exam-
ined withdrawal symptoms after dependence induced by a lower con-
stant dose of morphine (20 mg/kg) (Figure 3B). Two-way ANOVA 
revealed interaction between genotype and treatment (F(1,41) = 5.99, 
p < 0.05). Student’s t test analysis revealed a signiﬁ  cant increase in global 
symptoms score in TgNTRK3 as compared to WT mice (t(1,16) = −2.46, 
p < 0.05). No differences were observed in animals treated with saline 
plus naloxone (t(1,21) = −0.99, n.s., Student’s t test).
DECREASED ANXIETY BEHAVIOR OF TgNTRK3 MICE DURING 
WITHDRAWAL SYNDROME
Anxiety was evaluated in the zero-maze test during morphine 
withdrawal (Figure 4). No interaction between genotype and treat-
ment was revealed by two-way ANOVA in any of the quantiﬁ  ed 
behaviors (F(1,38) = 1.43, n.s., number of crossings; F(1,39) = 1.46, n.s., 
time spent in open arms; F(1,38) = 0.62, n.s., latency to open arms). 
However, TgNTRK3 mice showed a signiﬁ  cant increase in time 
spent in open arms (Figure 4A) during morphine withdrawal when 
compared to saline-treated transgenic mice after naloxone injection 
(t(1,19) = −2.24, p < 0.05, Student’s t test). The latency to enter in open 
arms (Figure 4B) was lower during morphine withdrawal in both 
TgNTRK3 (t(1,19) = 2.83, p = 0.01, Student’s t test) and WT mice, 
although the latter did not reach signiﬁ  cant differences (t(1,19) = 1.13, 
n.s., Student’s t test).
NT-3, BDNF AND THEIR RECEPTORS TrkC AND TrkB MRNAS LEVELS ARE 
DIFFERENTIALLY REGULATED AFTER CHRONIC MORPHINE 
ADMINISTRATION AND PRECIPITATED WITHDRAWAL IN TgNTRK3 MICE
To test whether opiate-induced regulation of neurotrophin expres-
sion was modiﬁ  ed in TgNTRK3 mice, coronal sections throughout 
the LC of saline-treated and morphine-treated mice were processed 
for in situ hybridization of NT-3, BDNF and TrkC, TrkB mRNAs 
(Figure 5; Table 1). Densitometric analysis of ﬁ  lm autoradiograms 
conﬁ  rmed the increased levels of TrkC mRNA that were previ-
ously reported in the LC (Dierssen et al., 2006) of TgNTRK3 after 
saline plus naloxone (t(1,95) = −2.66, p < 0.01, Student’s t test). These 
increased levels of TrkC mRNA were accompanied by an increase in 
NT-3 mRNA levels (t(1,55) = −3.53, p = 0.001, Student’s t test), thus 
conﬁ  rming previous data observed at the protein level (Dierssen 
et al., 2006).
After both chronic morphine treatment, and precipitated with-
drawal, NT-3 mRNA levels were not modiﬁ  ed with respect to saline 
plus naloxone neither in WT (F(2,82) = 2.12, n.s., one-way ANOVA) 
nor in TgNTRK3 (F(2,70) = 1.06, n.s., one-way ANOVA). However, 
in chronic morphine-treated mice, the levels of NT-3 were sig-
niﬁ  cantly higher in TgNTRK3 than in WT mice (t(1,35) = −3.17, Frontiers in Behavioral Neuroscience  www.frontiersin.org  February 2010  | Volume 3  |  Article 60  |  7
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FIGURE 3 | Global withdrawal score after naloxone administration 
in morphine (Mf)-treated mice. Mice received chronic treatment with 
(A) increasing or (B) constant doses of morphine. Withdrawal was precipitated 
in both groups by the administration of the opioid receptor antagonist, naloxone 
(Nlx, 1 mg/kg, s.c.). Somatic signs of withdrawal were recorded during 45 min, 
immediately after naloxone administration. The global withdrawal score was 
calculated for each animal by giving a relative weight to each withdrawal sign 
(see Materials and Methods). Data are expressed as means ± SEM. Sal: 
Control saline-treated animals. Tables represent the scores of the physical 
withdrawal symptoms.
p < 0.01, Student’s t test) but after precipitated withdrawal, no 
genotype-dependent differences were observed (t(1,58) = −0.58, 
n.s., Student’s t test). TrkC mRNA levels showed a decrease after 
both chronic morphine treatment and precipitated withdrawal, in 
TgNTRK3 (F(2,102) = 12.34, p < 0.001, one-way ANOVA) but not in 
WT mice (F(2,127) = 0.51, n.s., one-way ANOVA). Bonferroni post hoc 
analysis in TgNTRK3 mice revealed signiﬁ  cant differences respect 
to saline plus naloxone (p < 0.001), but not respect to chronic 
morphine treatment.
In contrast to the increase of TrkC mRNA levels observed in 
TgNTRK3 mice under saline plus naloxone conditions, TrkB 
mRNA levels were reduced as compared to WT mice (t(1,53) = 4.70, 
p < 0.001, Student’s t test), but no differences in BDNF mRNA 
levels were observed between genotypes (t(1,37) = 1.53, n.s., Student’s 
t test). TrkB mRNA expression levels were similarly reduced after 
chronic morphine administration showing no differences between 
 genotypes  (t(1,39) = 1.05, n.s., Student’s t test) but a signiﬁ  cantly 
greater decrease was observed in TgNTRK3 mice after precipi-
tated withdrawal (t(1,65) = 2.05, p < 0.05, Student’s t test). However, 
whereas the reduction in TrkB levels with respect to saline-treated 
mice was signiﬁ  cant in WT mice (F(2,80) = 11.00, p < 0.001; one-
way ANOVA), TgNTRK3 mice showed no differences in mRNA 
TrkB expression among treatment groups (F(2,81) = 1.02, n.s. one-
way ANOVA). Bonferroni post hoc analysis revealed signiﬁ  cant 
differences between saline and chronic morphine (p < 0.001) 
and also between saline and morphine withdrawal (p < 0.001) 
TgNTRK3 mice. The expression levels of BDNF changed after 
chronic morphine treatment and precipitated withdrawal in both 
WT (F(2,73) = 5.51,  p <  0.001, one-way ANOVA) and TgNTRK3 
mice (F(2,68) = 9.59, P < 0.001, one-way ANOVA), but a Bonferroni Frontiers in Behavioral Neuroscience  www.frontiersin.org  February 2010  | Volume 3  |  Article 60  |  8
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post hoc test showed signiﬁ  cant differences only in TgNTRK3 but 
not in WT mice when comparing chronic morphine treatment vs. 
saline (p < 0.001). However, signiﬁ  cant differences were observed in 
both genotypes when comparing precipitated withdrawal vs. saline 
(p < 0.01 in WT and p < 0.001 in TgNTRK3 mice).
To test whether the mRNA expression observed in the in situ 
hybridization was due to altered mRNA expression of endogenous 
TrkC in LC, we used Lightcycler qRT-PCR analysis. Data showed 
no differences in mRNA expression in brainstem of TgNTRK3 
mice (Table 2) using probes to discriminate between mouse and 
human receptors. The statistical analysis showed no signiﬁ  cant dif-
ferences in endogenous TrkC FL (1.01 ± 0.33, p = 0.93, n.s.) and 
Trkc TF (1.00 ± 0.25, p = 0.91, n.s.) expression of TgNTRK3 mice 
with respect to WT.
NTRK3 OVEREXPRESSION ALTERS NORADRENERGIC NEURONAL 
ACTIVITY AND OCCLUDES MORPHINE-INDUCED FUNCTIONAL 
ADAPTATIONS IN THE LC
An elevated activity of LC neurons has been postulated to contrib-
ute to the expression of opiate withdrawal in morphine-dependent 
rats (Kogan et al., 1992). To examine whether the TrkC receptor 
regulates this withdrawal-induced hyperactivity, single-unit extra-
cellular recordings of LC neurons were obtained in brain slices 
from WT and TgNTRK3 mice. Spontaneous ﬁ  ring rates were 
recorded during in vitro opioid withdrawal in a total of 192 LC 
cells (on average, 6 cells/slice) from mice chronically treated with 
morphine or saline. After saline treatment, ﬁ  ring rate values of LC 
neurons in WT animals (0.75 ± 0.1, n = 8) were within the range 
  previously reported in rat brain slices (Kogan et al., 1992). In vitro 
opiate withdrawal in morphine-treated WT mice increased the ﬁ  r-
ing rates of LC cells (+73%, n = 8, p < 0.05) compared to the values 
in the corresponding saline-treated group (Table 3; Figure 6A). The 
magnitude of this increase was similar to that previously reported 
in slices from morphine-dependent mice (Martin et al., 2003). 
Paradoxically, although ﬁ  ring rates in TgNTRK3 after saline treat-
ment were signiﬁ  cantly elevated with respect to WT (1.28 ± 0.1 Hz, 
n = 8; p < 0.05) (Table 3; Figure 6A), they were not signiﬁ  cantly 
elevated during opiate withdrawal (n = 8) with respect to WT or 
saline-treated groups (Table 3; Figure 6A), suggesting that TrkC 
receptor overexpression is able to mimic and thereby occlude mor-
phine-induced functional adaptations in the LC. The  possibility of 
residual morphine present in the slice from dependent animals was 
explored by the administration of naloxone immediately after the 
cell sampling: naloxone (1 µM) failed to change the ﬁ  ring rate of 
LC cells in either group (data not shown).
To further characterize the changes found in the LC from mice 
overexpressing TrkC, we tested the functionality of µ-opioid recep-
tors by constructing concentration-effect curves for ME in chroni-
cally morphine- and saline-treated mice. In WT mice, treatment 
with increasing doses of morphine induced a moderate degree of 
opioid tolerance in the LC, as revealed by a rightward shift in the 
concentration-effect curves (Figure 6B) and a 4-fold increase in the 
EC50 for ME (n = 9) compared to the saline group (n = 8; One-way 
ANOVA, F(3,25) = 3.16; post hoc, p < 0.05; Table 3). Interestingly, 
FIGURE 4 | Zero-maze test during withdrawal syndrome. The anxiogenic 
effects of morphine withdrawal were studied using the zero-maze test 
immediately after evaluation of withdrawal symptoms in animals receiving 
constant doses of morphine (20 mg/kg). (A) Time spent in open zone. 
(B) Latency to enter the open zone. (C) Number of crossings. Data are 
expressed as means ± SEM. *p < 0.05, **p < 0.01.Frontiers in Behavioral Neuroscience  www.frontiersin.org  February 2010  | Volume 3  |  Article 60  |  9
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the EC50 value obtained from concentration-effect curves for ME 
in saline-treated TgNTRK3 mice was also signiﬁ  cantly shifted to 
the right (n = 4, p < 0.05) compared to that in the corresponding 
WT group (n = 8; Table 3). However, after chronic treatment with 
morphine in TgNTRK3 mice no further change was observed in the 
EC50 value for ME (n = 8) as compared to the corresponding curve 
in saline-treated mice (Table 3). In fact, concentration-effect curves 
in morphine-treated TgNTRK3 mice were not different from those 
in morphine-treated WT mice (Figure 6B; Table 3),   conﬁ  rming 
that TrkC receptor overexpression occludes morphine-induced 
functional adaptations in the LC.
DISCUSSION
In the present work, constitutive TrkC overexpression in a model 
of panic disorder, TgNTRK3 mice (Dierssen et al., 2006), dra-
matically alters spontaneous ﬁ  ring rates of LC neurons and the 
FIGURE 5 | In situ hybridization of TrkC, TrkB and their ligands after chronic 
morphine administration and precipitated withdrawal. (A) Expression of TrkC, 
NT-3, TrkB and BDNF given as percentage of intensity for the region of interest (% 
of ROI) in WT (white bars) and TgNTRK3 (black bars) mice. (B) Diagram showing 
the locus coeruleus (LC) localization and photomicrographs of consecutive 14 µm 
coronal sections labeled with TH antibody (1:8000; Sigma, MO, USA) served to 
deﬁ  ne the LC counting area (left-lower panel). Photomicrographs of 14 µm coronal 
sections (right-lower panel) illustrate TrkC and TrkB expression in the LC of WT and 
TgNTRK3 mice. Data are expressed as means ± SEM. *p < 0.05, **p < 0.01, 
***p < 0.005 when compared with the corresponding WT group (Student’s t test), 
and †p < 0.05, ††p < 0.01, †††p < 0.005 when compared with the corresponding 
saline group (Student’s t test).Frontiers in Behavioral Neuroscience  www.frontiersin.org  February 2010  | Volume 3  |  Article 60  |  10
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Table 1 | In situ hybdridization of TrkC, TrkB and their ligands after chronic morphine administration and precipitated withdrawal.
 Sal  + Nlx  Chronic Mf  Mf + Nlx
 WT  TgNTRK3  WT  TgNTRK3  WT  TgNTRK3
TrkC 7 .69  ± 0.56  10.56 ± 1.00**  8.97 ± 1.70  8.07 ± 0.85  7 .84 ± 0.63  4.92 ± 0.68**
NT-3 1.46  ± 0.09  1.99 ± 0.12***  1.65 ± 0.11  2.36 ± 0.21**  1.92 ± 0.22  2.09 ± 0.18
TrkB 16.05  ± 0.81  10.09 ± 0.96***  9.86 ± 1.12  8.25 ± 1.03  11.18 ± 0.93  8.30 ± 1.06*
BDNF 5.92  ± 1.00  4.28 ± 0.30  7 .76 ± 0.95  7 .93 ± 0.90  9.85 ± 0.79  7 .89 ± 0.47*
TgNTRK3 and WT littermates were used for each treatment condition following the increasing dose morphine injection schedule. Data are given as percentage of 
intensity for the region of interest (% of ROI) ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t test, WT vs. TgNTRK3 mice).
Table 2 | Quantitative RT-PCR analysis of TrkC full-length isoform (FL) 
and TrkC truncated isoform (TF).
Gene Fold-Change*  Std.  error  p-value  Sig.
TrkC FL  1.01  0.33  0.93  n.s.
TrkC TF  1.00  0.25  0.91  n.s.
Fold-change*: Endogenous TrkC receptor expression in TgNTRK3 with respect 
to WT mice. Pair Wise Reallocation Randomisation Test© (Relative Expression 
Software Tool – 384 (REST-384© v.2).
response of the noradrenergic system to chronic opiate exposure, 
possibly related to the paradoxical regulation of neurotrophic 
peptides observed in this model. Notably, TgNTRK3 LC neu-
rons showed an increased ﬁ  ring rate in saline-treated conditions 
and profound abnormalities in their response to ME. In contrast, 
the behavioral withdrawal pattern was not modiﬁ  ed, nor were 
either the development of tolerance or the locomotor sensitiza-
tion to morphine when it was administered at increasing doses. 
Conversely, chronic constant doses of morphine induced a signiﬁ  -
cantly increased behavioral withdrawal syndrome in TgNTRK3.
LC is involved in the pathogenesis of panic disorder (Protopopescu 
et al., 2006) and has served as a model system for the pharmacology 
and cellular basis of opiate tolerance, dependence, and withdrawal 
(Nestler and Aghajanian, 1997). Several studies have suggested 
that panic attacks might be the consequence of hyperactivity of 
LC noradrenergic cells (David Johnson, 2003; Valenca et al., 2004) 
and changes in the expression of neurotrophins and their receptors 
are essential for opiate-induced adaptations (Numan et al., 1998; 
Akbarian et al., 2001, 2002; Hatami et al., 2007). In the present work 
we observed profound abnormalities in LC neuronal responses in 
basal conditions and after chronic opiate exposure in TgNTRK3 
mice. Spontaneous LC neurons basal ﬁ  ring rates of TgNTRK3 mice 
were abnormally elevated with respect to WTs. These neurons pos-
sess µ-opioid receptors and are innervated by enkephalin and endor-
phin ﬁ  bers (Strahlendorf et al., 1980; Drolet et al., 1992). Similarly, 
exogenous opioid agonists, acting at µ receptors, produce inhibi-
tion of LC cells, a pharmacological inhibition reversed by opioid 
antagonists such as naloxone, which in turn induces hyperactivity 
of noradrenergic cells. The nucleus paragigantocellularis (Ennis and 
Aston-Jones, 1988), which has been implicated in the hyperactivity 
of LC neurons during withdrawal, is an important source of NT-3 
and BDNF (Rasmussen and Aghajanian, 1989) to the LC.
In fact, deregulation of the brainstem opioid system may 
underlie critical aspects of panic disorder neurobiology, since 
clinical studies show that normal subjects experience strong 
physiological reactivity to naloxone–lactate (Sinha et al., 2007) 
although other studies (Liebowitz et  al., 1984) found that 
panic patients’ response to lactate infusion was not modulated 
by naloxone pretreatment. This lack of effect of naloxone in 
panic patients has been interpreted as a tonic or phasic opioid 
hypofunction, although in some cases panic attacks can be pre-
cipitated by the administration of naltrexone in a subgroup of 
panic disorder patients (Maremmani et al., 1998). We tested the 
functionality of µ-opioid receptors in the LC of TgNTRK3 mice, 
by constructing concentration-effect curves for ME in chroni-
cally morphine- and saline-treated mice. Interestingly, the EC50 
value for ME in saline-treated TgNTRK3 mice was signiﬁ  cantly 
increased compared to the corresponding WT group. These 
results suggest that overexpression of TrkC leads to hypofunc-
tion of opioid receptors, and to a reduced endogenous inhibitory 
control of LC neurons. Consistently with these results, TgNTRK3 
mice present a signiﬁ  cantly reduced acute antinociceptive effect 
of morphine.
It could be argued that an increased excitatory afferent input 
to the LC could contribute to disinhibition of noradrenergic neu-
rons (Williams and North, 1984; Akaoka and Aston-Jones, 1991; 
Aghajanian et al., 1994). However, in our experiments, given the 
fact that the recordings were conducted on coronal slice prepara-
tions that disrupt afferent inputs of the LC, it is unlikely that the 
observed increase in LC neuronal ﬁ  ring in the mutants is caused 
by an imbalance between GABAergic and glutamatergic excitatory 
signal transmission (Van Bockstaele et al., 2000) to the LC. In fact, 
in WT mice, treatment with morphine induced a rightward shift 
in the concentration-effect curves for ME that revealed a moderate 
degree of opioid tolerance, but no change was observed in the ME 
EC50 in TgNTRK3 mice. Thus, we monitored the development of 
tolerance and sensitization over the course of several days, and we 
observed that both TgNTRK3 and control mice developed a similar 
change in morphine responsiveness, indicating that neither toler-
ance nor sensitization were affected by TrkC overexpression. It is 
tempting to suggest that TrkC receptor overexpression is able to 
mimic and thereby occlude morphine-induced functional adapta-
tions in the LC, suggesting that overexpression of TrkC could be a 
mechanism in the noradrenergic plasticity in LC (Akbarian et al., 
2001, 2002).Frontiers in Behavioral Neuroscience  www.frontiersin.org  February 2010  | Volume 3  |  Article 60  |  11
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increase in anxiety in humans and mouse models (Schulteis et al., 
1998), we tested the possible anxiogenic effects of withdrawal in 
our panic disorder mouse model. Surprisingly, in our experi-
ments using the zero-maze test we could not detect an increase 
in anxiety-like behaviors in either WT or TgNTRK3. Conversely 
both genotypes spent more time in the aversive zones but this 
reduced anxiety levels were more clear in TgNTRK3 mice. This 
supports the possibility that zero-maze test behaviors might not 
be driven exclusively by anxiety levels but rather by other with-
drawal-induced behaviors, as has been reported using the elevated 
plus maze (Hodgson et al., 2008; Buckman et al., 2009).
Increased TH expression and catalytic activity (Guitart et al., 
1990; Lane-Ladd et al., 1997; Boundy et al., 1998) in the LC is con-
sidered a key element in the neuroadaptations produced by chronic 
morphine administration has been shown to. This upregulation 
of TH would be expected to increase the capacity of noradren-
ergic neurons to synthesize norepinephrine, which then could 
contribute to the dramatic increase in norepinephrine release 
and to behavioral changes described during opiate withdrawal 
(Koob, 1992; Grasing et al., 1997). In TgNTRK3 mice, we previ-
ously described an up-regulation of TH that may be due to the 
increased cell numbers in LC (Dierssen et al., 2006). Therefore, one 
would predict that the TH upregulation in the LC of TgNTRK3 
mice would contribute to the increased basal LC activity, observed 
in the present work.
In our model, it was also relevant to establish the possible 
modiﬁ  cations in neurotrophin expression, since the NT-3/TrkC 
system has been suggested to interfere with the biological effects 
of opiates through direct effects on noradrenergic neurons. 
NT-3 opposes, in vitro, the decline in embryonic A6 neuron 
numbers after chronic morphine exposure (Sklair-Tavron and 
Nestler, 1995) and mice with a CNS-wide deletion of NT-3 had 
attenuated withdrawal reactions that were restored by trans-
gene-derived overexpression of NT-3 in noradrenergic neurons 
(Akbarian et al., 2001). In TgNTRK3 mice the LC phenotype 
could thus emanate from the alteration of both BDNF and NT-3 
systems. Interestingly, neurotrophins can recover a noradrenergic 
phenotype in ‘resting noradrenergic’ neurons in the adult LC 
(Bezin et al., 2000), a mechanism that could be involved in the 
pathological alteration of LC in psychiatric conditions such as 
panic disorder or substance abuse. Chronic opiate treatment and 
Table 3 | Effect of morphine on the spontaneous ﬁ  ring rate and on the inhibition induced by ME in LC neurons from WT and TgNTRK3 mice.
  Concentration-effect curves2
Treatment groups1    Firing rate (Hz)  n   Log EC50 (EC50 μM) Slope  factor  n
Saline WT  7 .52  ± 0.10  8 -6.01  ± 0.10  (0.97)  0.89 ± 0.15  8
 TgNTRK3  12.78  ± 1.30†  8 -5.44  ± 0.28*  (3.62)  0.74 ± 0.11  4
Morphine WT  12.34  ± 1.40*  8 -5.56  ± 0.13† (2.74)  1.11  ± 0.32  9
 TgNTRK3  10.86  ± 1.11  8 -5.62  ± 0.10  (2.38)  0.92 ± 0.06  8
1Animals were treated chronically with saline or morphine for 5 days. Recordings were performed 1.5 h after slice preparation to allow morphine to wash out. 
2Parameters of concentration-effect curves for ME were estimated in each experiment by nonlinear regression. EC50 values (concentration needed to elicit a 50% of 
maximal effect) and slope factors are shown as mean ± SEM of n experiments. Maximal effect values were 100% in all cases. *p < 0.05 when compared with the 
corresponding WT group; †p < 0.05 when compared with the corresponding saline group (one-way ANOVA followed by a post hoc Student’s or Tukey’s t test).
Regarding opioid withdrawal, electrophysiological studies have 
shown that after chronic morphine treatment, naloxone-induced 
withdrawal triggers intense hyperactivity of LC neurons that is 
prevented by clonidine treatment (Taylor et al., 1988; Kogan et al., 
1992). In our experiments, LC cells from WT mice chronically 
treated with morphine showed the typical hyperactivation during 
in vitro withdrawal. However, this elevation of ﬁ  ring rates dur-
ing opioid withdrawal was not observed in TgNTRK3 mice, thus 
suggesting that the neuronal adaptations that take place during 
chronic morphine treatment had not been produced in TgNTRK3 
mice. Since an increase in LC activity has been argued to be 
both necessary and sufﬁ  cient to induce most opiate   withdrawal 
 behaviors (Grant et al., 1988; Maldonado and Koob, 1993; Nestler 
and Aghajanian, 1997), the fact that the LC ﬁ  ring rate was not 
further increased by morphine withdrawal in TgNTRK3 mice 
would be in accordance with previous studies showing that lesions 
affecting the LC do not abolish opiate withdrawal reactions 
(Christie et al., 1997; Caille et al., 1999; Delfs et al., 2000). Thus, 
we decided to investigate the behavioral withdrawal   syndrome. 
Using increasing doses of morphine, we did not observe qualita-
tive or quantitative differences in somatic or behavioral with-
drawal signs between WT and TgNTRK3 animals. In fact, the 
spontaneous ﬁ  ring rates of LC neurons of morphine-treated 
mice using the same dosage regime were not different between 
both genotypes. However, it has been argued that decreasing the 
dose or duration of morphine administration can reduce drug’s 
withdrawal behavioral symptoms thus increasing the sensitivity 
of the assay (Haghparast et al., 2008). In fact, in TgNTRK3 mice 
constant low doses of morphine induced a signiﬁ  cantly more 
intense behavioral withdrawal syndrome. This suggests that a 
ceiling effect may have been reached in the previous experiment, 
and that the appearance of adverse effects may have hidden the 
real withdrawal signs. This ceiling effect may be explained either 
by an opposing effect of down-regulated TrkC in TgNTRK3 mice 
treated with increasing doses of morphine (see Figure 5A) or by 
the fact that LC neurons from TgNTRK3 mice are more resistant 
to opioid inhibition (see Figure 6), which would attenuate induc-
tion of spontaneous hyperactivity during morphine withdrawal 
as shown by Cruz et al. (2008). Alternatively, other structures 
than the LC that are regulated by morphine may participate in 
opiate withdrawal. Also, since withdrawal has been related to an Frontiers in Behavioral Neuroscience  www.frontiersin.org  February 2010  | Volume 3  |  Article 60  |  12
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noradrenergic system in response to opiate exposure (Numan 
et  al., 1998; Akbarian et  al., 2001, 2002). It has been shown 
(Numan et al., 1998), that chronic morphine exposure resulted 
in modest increases in BDNF and NT-3 but unchanged TrkB or 
TrkC mRNA expression in LC, while precipitated withdrawal leads 
to a marked, rapid, and prolonged increase in BDNF mRNA, a 
delayed decrease in NT-3 mRNA, and to an elevation of both TrkB 
and TrkC mRNAs at 2 and 6 h of withdrawal in the rat. In our 
experiments, chronic morphine treatment led to small changes 
in NT-3 and BDNF mRNA levels and precipitated opiate with-
drawal resulted in a robust increase in BDNF along with a slight 
decrease in NT-3 mRNA levels in WT mice. However, in contrast 
to previous observations, TrkC was not modiﬁ  ed after chronic 
morphine treatment, but a robust decrease in TrkB expression 
was observed in WT mice. In TgNTRK3 mice we observed a 
different regulation of NT-3, BDNF and their receptors TrkC 
and TrkB mRNA after chronic morphine administration and 
precipitated withdrawal. These data suggest that variable com-
binations and intensities of neurotrophin-  signaling pathways 
in neuronal circuits that are interconnected with noradrenergic 
neurons could adjust and ﬁ  ne-tune opiate-related adaptations 
of the noradrenergic system.
In conclusion, we show here that the NT-3/TrkC is an important 
regulator of neuronal ﬁ  ring in LC and would contribute to the 
adaptations of the noradrenergic system in response to chronic 
opiate exposure. These results may explain the perturbation of 
naloxone response in panic disorder patients and naltrexone-
induced panic attacks (Arntz et al., 1993; Maremmani et al., 1998; 
Sinha et al., 2007). It remains to be elucidated whether the molecu-
lar mechanisms that mediate NT-3/TrkC neuronal plasticity in 
the noradrenergic system beyond these opiate-induced adapta-
tions resemble those that operate in the hippocampus, where the 
overexpression of TrkC markedly increases synaptic activity and 
LTP (Sahún et al., 2007a). We propose that TrkC may act as a 
putative genetic interface for the co-occurrence of panic disorder 
and substance abuse.
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FIGURE 6 | Effect of morphine withdrawal on spontaneous ﬁ  ring rate of 
LC neurons and concentration-effect curves for met-enkephalin 
(ME)-induced inhibition. (A) To assess whether physical withdrawal signs 
of TgNTRK3 mice were paralleled at the cellular level by increased activities 
of LC neurons, we recorded the ﬁ  ring rates of these neurons in slices from 
WT (black bars) and TgNTRK3 animals (white bars) treated with saline or 
morphine. Single-unit extracellular recordings were performed 2 h after 
slices preparation to allow morphine to wash out. Bars represent the 
mean ± SEM. *p < 0.05 when compared with the corresponding WT group; 
†p < 0.05 when compared with the corresponding saline group (one-way 
ANOVA followed by a Tukey’s multiple comparison t test). (B) Concentration-
effect curves were constructed for the inhibitory effect of the µ-opioid 
receptor agonist ME on the LC, by adding increasing concentrations of the 
drug (0.1–100 µM, 3.3×) at 5-min intervals until a maximal effect was 
reached. The horizontal axis represents the logarithmic value of ME 
concentrations. The vertical axis expresses the percentage of reduction in the 
ﬁ  ring rate from the basal rate. Data are mean ± SEM. at each ME 
concentration. The lines are the theoretical curves in each group constructed 
from the mean of the individual concentration-effect curve parameters, as 
estimated by nonlinear regressions (see Materials and Methods for details 
and Table 3 for mean values). In all groups, the maximal effect of ME was 
100% of baseline.
withdrawal differentially regulate neurotrophin and their recep-
tor mRNAs in catecholaminergic nuclei (Seroogy et al., 1994; 
Hung and Lee, 1996; Numan et al., 1998; Numan and Seroogy, 
1999). Concretely, both BDNF/TrkB and NT-3/TrkC systems have 
been proposed to regulate the neurochemical adaptations of the Frontiers in Behavioral Neuroscience  www.frontiersin.org  February 2010  | Volume 3  |  Article 60  |  13
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